Search

Author/Creator Turner, Christopher D

1. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. Issue 2 (December 2017)

Authors:
Weller, Michael; Butowski, Nicholas; Tran, David D; Recht, Lawrence D; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M; Wong, Mark; Hamilton, Mark G; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer;...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 2(2017:Feb.)
Page Start:
e709
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Issue 8 (August 2021)

Authors:
Subbiah, Vivek; Hu, Mimi I; Wirth, Lori J; Schuler, Martin; Mansfield, Aaron S; Curigliano, Giuseppe; Brose, Marcia S; Zhu, Viola W; Leboulleux, Sophie; Bowles, Daniel W; Baik, Christina S; Adkins, Douglas; Keam, Bhumsuk; Matos, Ignacio; Garralda, Elena; Gainor, Justin F; Lopes, Gilberto; Lin, Ch...
Journal:
Lancet
Issue:
Volume 9:Issue 8(2021)
Page Start:
491
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Issue 7 (July 2021)

Authors:
Gainor, Justin F; Curigliano, Giuseppe; Kim, Dong-Wan; Lee, Dae Ho; Besse, Benjamin; Baik, Christina S; Doebele, Robert C; Cassier, Philippe A; Lopes, Gilberto; Tan, Daniel S W; Garralda, Elena; Paz-Ares, Luis G; Cho, Byoung Chul; Gadgeel, Shirish M; Thomas, Michael; Liu, Stephen V; Taylor, Matth...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 7(2021)
Page Start:
959
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Issue 10 (October 2017)

Authors:
Weller, Michael; Butowski, Nicholas; Tran, David D; Recht, Lawrence D; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M; Wong, Mark; Hamilton, Mark G; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer;...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 10(2017:Oct.)
Page Start:
1373
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗